Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register

Abstract

Background:

Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available.

Objectives:

To compare diagnostic performances of two different data-driven SPMS definitions.

Methods:

Data-driven SPMS definitions based on a version of Lorscheider’s algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist’s definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC).

Results:

A cohort of 10,240 MS patients with ⩾5 years of follow-up was extracted from the Italian MS Registry; 880 (8.5%) patients were classified as SPMS according to the neurologist definition, 1806 (17.6%) applying the DDA and 1134 (11.0%) with the EXPAND definition. The DDA showed greater discrimination power (AUC: 0.8 vs 0.6) and a higher sensitivity (77.1% vs 38.0%) than the EXPAND definition, with similar specificity (88.0% vs 91.5%). PPV and NPV were higher using the DDA than considering EXPAND definition (37.5% vs 29.5%; 97.6% vs 94.0%).

Conclusion:

Data-driven definitions demonstrated greater ability to capture SP transition than neurologist’s definition and the global accuracy of DDA seems to be higher than the EXPAND definition.

Keywords

Multiple sclerosis secondary progressive disease registry big data prognosis data-driven algorithm

Get full access to this article

View all access options for this article.

References

Antel

Caramanos

, et al. Primary progressive multiple sclerosis: Part of the MS disease spectrum or separate disease entity? Acta Neuropathol 2012; 123(5): 627–638.

Fransen

Crusius

JBA

Smolders

, et al. Post-mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms. Brain Pathol 2020; 30(1): 106–119.

Lublin

Reingold

Cohen

, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83(3): 278–286.

Lassmann

van Horssen

Mahad

. Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol 2012; 8(11): 647–656.

Coetzee

Thompson

. Unified understanding of MS course is required for drug development. Nat Rev Neurol 2018; 14(4): 191–192.

Eshaghi

Prados

Brownlee

, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 2018; 83(2): 210–222.

Khalil

Teunissen

Otto

, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14(10): 577–589.

Filippi

Bruck

Chard

, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2019; 18(2): 198–210.

Lorscheider

Buzzard

Jokubaitis

, et al. Defining secondary progressive multiple sclerosis. Brain 2016; 139(Pt 9): 2395–2405.

10.

Iaffaldano

Lucisano

Patti

, et al. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Mult Scler 2021; 27(3): 430–438.

11.

Kappos

Bar-Or

Cree

BAC

, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study [published correction appears in Lancet.2018; 392(10160): 2170. Lancet 2018; 391(10127): 1263–1273.

12.

Study Results – ClinicalTrials.gov. Exploring the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (EXPAND), https://clinicaltrials.gov/ct2/show/NCT01665144

13.

Ontaneda

Fox

. Progressive multiple sclerosis. Curr Opin Neurol 2015; 28(3): 237–243.

14.

Trojano

Bergamaschi

Amato

, et al. The Italian multiple sclerosis register [published correction appears in Neurol Sci.2019; 40(4): 907]. Neurol Sci 2019; 40(1): 155–165.

15.

Lublin

Reingold

. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907–911.

16.

Lassmann

Bradl

. Multiple sclerosis: Experimental models and reality. Acta Neuropathol 2017; 133(2): 223–244.

17.

Katz Sand

Krieger

Farrell

, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 2014; 20(12): 1654–1657.

18.

University of California San Francisco MS-EPIC Team, Cree

BAC

Hollenbach

, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 2019; 85(5): 653–666.

19.

Kappos

Wolinsky

Giovannoni

, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 2020; 77(9): 1132–1140.

20.

Kalincik

Cutter

Spelman

, et al. Defining reliable disability outcomes in multiple sclerosis. Brain 2015; 138(Pt 11): 3287–3298.

21.

Ravnborg

Blinkenberg

Sellebjerg

, et al. Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. Mult Scler 2005; 11(1): 81–84.

22.

Bergamaschi

Berzuini

Romani

, et al. Predicting secondary progression in relapsing-remitting multiple sclerosis: A Bayesian analysis. J Neurol Sci 2001; 189(1–2): 13–21.

23.

Kopp

Bramow

Illes

, et al. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population. Mult Scler Relat Disord 2021; 56: 103319.

24.

Trojano

Pellegrini

Fuiani

, et al. New natural history of interferon beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61(4): 300–306.

25.

Bergamaschi

Quaglini

Tavazzi

, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler 2016; 22(13): 1732–1740.

26.

Iaffaldano

Lucisano

Butzkueven

, et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler 2021; 27(10): 1543–1555.

27.

Tedeholm

Lycke

Skoog

, et al. Time to secondary progression in patients with multiple sclerosis treated with first generation immunomodulating drugs. Mult Scler 2013; 19: 765–774.

28.

Brown

JWL

Coles

Horakova

, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321(2): 175–187.